Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company’s debt.
Valeant did not disclose the number of shares it plans to sell.
More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.